Arbutus Biopharma Corporation

NasdaqGS:ABUS Stock Report

Market Cap: US$490.0m

Arbutus Biopharma Dividend

Dividend criteria checks 0/6

Arbutus Biopharma does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$0.41
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Feb 10
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 03
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Nov 09
Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

Oct 24
Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Apr 26
We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

Nov 11
Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Oct 28
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'

Sep 12

Arbutus stock rises on US patent linked to hepatitis B therapy AB-729

Aug 30

Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Aug 06
Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial

Jul 20

Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release

Jun 29

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Jun 15
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

May 11
Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Mar 08
Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest

Mar 07

Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?

Dec 17

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Dec 14
Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment

Nov 20

Arbutus Biopharma: A First Assessment

Sep 15

We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Sep 11
We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment

Jun 29

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

May 21
Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Arbutus Bio slips 4% as Q1 revenue trails consensus

May 05

What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition

Mar 12
What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Feb 02
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years

Jan 07
Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years

Arbutus Biopharma (ABUS) Investor Presentation - Slideshow

Dec 17

What Is The Ownership Structure Like For Arbutus Biopharma Corporation (NASDAQ:ABUS)?

Dec 12
What Is The Ownership Structure Like For Arbutus Biopharma Corporation (NASDAQ:ABUS)?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ABUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABUS's dividend payments have been increasing.


Dividend Yield vs Market

Arbutus Biopharma Dividend Yield vs Market
How does ABUS dividend yield compare to the market?
SegmentDividend Yield
Company (ABUS)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (ABUS)n/a

Notable Dividend: Unable to evaluate ABUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ABUS's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ABUS has not reported any payouts.


Discover strong dividend paying companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.